Page last updated: 2024-10-30
lamotrigine and Hemisensory Neglect
lamotrigine has been researched along with Hemisensory Neglect in 1 studies
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Anand, A | 1 |
| Charney, DS | 1 |
| Oren, DA | 1 |
| Berman, RM | 1 |
| Hu, XS | 1 |
| Cappiello, A | 1 |
| Krystal, JH | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| An Investigation of the Antidepressant Efficacy and Safety of an AMPAkine (Org 24448) in Major Depressive Disorder, A Double-Blind, Placebo-Controlled, Randomized Study[NCT00113022] | Phase 2 | 9 participants (Actual) | Interventional | 2005-05-31 | Terminated (stopped due to Terminated due to concerns about adverse events in separate study.) |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Montgomery-Asberg Depression Rating Scale (MADRS)
The MADRS is a measure of depression severity examined on a weekly basis. The minimum score on the 10 item scale is 0 indicating no depression. The maximum score is 60 indicating a very severe depression. Scores of 18 and above are generally considered to suggest significant levels of depression. (NCT00113022)
Timeframe: 8 weeks
| Intervention | Scores on a scale (Least Squares Mean) |
|---|
| Org 24448 | 26.425 |
| Placebo | 24.205 |
Trials
1 trial available for lamotrigine and Hemisensory Neglect